Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer

被引：24

作者：

Emmanouilides C. ^{[1
,2
]}

Pegram M. ^{[1
]}

Robinson R. ^{[1
]}

Hecht R. ^{[1
]}

Kabbinavar F. ^{[1
]}

Isacoff W. ^{[1
]}

机构：

[1] Division of Hematology/Oncology, UCLA Medical Center, Los Angeles

[2] Interbalkan Medical Center, 57001 Pylaia, Thessaloniki

来源：

Techniques in Coloproctology | 2004年 / 8卷 / Suppl 1期

关键词：

Bevacizumab; Colorectal cancer; Refractory; Treatment;

D O I：

10.1007/s10151-004-0110-4

中图分类号：

学科分类号：

摘要：

Background: To evaluate the activity and safety of bevacizumab when given with standard 5FU/leukovorin (LV) regimens in patients with metastatic colorectal cancer who have failed irinotecan and oxaliplatin-based treatments. Methods: Bevacizumab was given at 5 mg/kg as an IV infusion every 2 weeks. Patients received 5FU according to Roswell Park or the de Gramont regimen. Results: Nineteen patients enrolled, median age 60, median PS: 1. Most common toxicity attributable to bevacizumab was mild hypertension, epistaxis and mild proteinuria; 1 patient had a CNS haemorrhage. The median number of cycles was 1 (8 weeks). Clinical benefit as disease stabilisation lasting 2-6 months was noted in 9 patients, whereas 10 progressed (median f/u: 5 months). TTP was 16 weeks, and the overall survival has not been reached (24+ weeks). Conclusions: Bevacizumab may result in growth arrest and clinical benefit in a substantial proportion of patients with colorectal cancer and no alternative treatment.

引用

页码：S50 / S52

页数：2

共 7 条

[1]

Frank R.E., Saclarides T.J., Leurgans S., Et al., Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer, Ann Surg, 222, pp. 695-699, (1995)

[2]

Kanellos I., Zacharakis E., Demetriades H., Betsis D., Surgical management of colorectal cancer, Medimond Int Proc, 4, pp. 275-277, (2003)

[3]

Kanellos I., Demetriades H., Zintzaras E., Mandrali A., Mantzoros I., Betsis D., Incidence and prognostic value of positive peritoneal cytology in colorectal cancer, Dis Colon Rectum, 46, pp. 535-539, (2003)

[4]

Kanellos I., Zacharakis E., Christoforidis E., Demetriades H., Betsis D., Low anterior resection without defunctioning stoma, Tech Coloproctol, 6, pp. 153-157, (2002)

[5]

Borgstrom P., Gold D.P., Hillan K.J., Et al., Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin, Anticancer Res, 19, pp. 4203-4214, (1999)

[6]

Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Et al., Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, pp. 60-65, (2003)

[7]

Hurwitz H., Fehrenbacher L., Cartwright T., Et al., Bevacizumab prolongs survival as first-line therapy in subjects with metastatic CRC, Proc Am Soc Clin Oncol, 22, (2003)

← 1 →